WebLONSURF® CLASSIFICATION: antimetabolite. Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION: … WebIrinotecan and capecitabine is a chemotherapy combination known as XELIRI, CAPIRI and IrCap. It is a treatment for bowel cancer that has spread to other parts of the body. When …
ANEXA I REZUMATUL CARACTERISTICILOR PRODUSULUI
Web19 de jan. de 2024 · Recommended Dosage The recommended dosage of LONSURF is 35 mg/m 2 up to a maximum of 80 mg per dose (based on the trifluridine component) orally … WebSevere Myelosuppression: LONSURF caused severe and life‑threatening myelosuppression (Grade 3‑4) consisting of neutropenia (38%), anemia (18%), thrombocytopenia (5%), and febrile neutropenia (3%). Two patients (0.2%) died due to neutropenic infection. A total of 12% of LONSURF‑treated patients received granulocyte‑colony stimulating ... companies act ghg regs. 2013
HIGHLIGHTS OF PRESCRIBING INFORMATION CONTRAINDICATIONS LONSURF ...
Web14 de mai. de 2015 · TAS-102 (tipiracil hydrochloride) is an oral drug that combines two agents, trifluridine and tipiracil hydrochloride. Trifluridine incorporates into DNA, and this process may result in the drug’s antitumor effects. Tipiracil hydrochloride helps to maintain blood concentrations of trifluridine by inhibiting an enzyme that degrades trifluridine. Web27 de jan. de 2024 · Trifluridine–tipiracil (Lonsurf) ... Macmillan Cancer Support, 0808 808 00 00; Cancer Research UK Patient Information, 0808 800 4040; You can also get … Web13 de jan. de 2024 · Lonsurf is available as tablets (15 mg trifluridine and 6.14 mg tipiracil; 20 mg trifluridine and 8.19 mg tipiracil) and is given in treatment cycles of 28 days. The dose is calculated using the patient’s height and weight. The tablets are taken twice a day on certain days of each treatment cycle. companies act going concern